Shields Tammy S, Brinton Louise A, Burk Robert D, Wang Sophia S, Weinstein Stephanie J, Ziegler Regina G, Studentsov Yevgeniy Y, McAdams Mary, Schiffman Mark
Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, 6120 Executive Boulevard, MSC 7234, Rockville, MD 20852, USA.
Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1574-82.
Oncogenic human papillomavirus (HPV) infections, the necessary cause of most cervical cancers, are common and usually clear within 1 to 2 years. Identifying cofactors that lead to cancer among HPV-infected women has depended mainly on case-control studies defining HPV by DNA testing. DNA testing assesses only current infection; thus, concerns about residual confounding remain. To assess cofactors, we used seropositivity to five oncogenic HPV types as a marker of past exposure and confined our analysis to seropositive controls compared with cancer cases. Study subjects had participated in a multicenter U.S. case-control study conducted in the early 1980s. The detailed questionnaire and stored sera for 235 cases of squamous carcinoma and 486 controls motivated the reanalysis. We measured antibodies to HPV types 16, 18, 31, 45, and 52. Independent, significant predictors of seropositivity among controls included numbers of sexual partners, Black race, and oral contraceptive use. Condom use was protective. Among HPV-exposed women, Papanicolaou screening, Black race, and yeast infection were significantly associated with reduced cancer risk. Current smoking was associated with a 2-fold increase in risk; there were independent, significant trends of increased risk with numbers of cigarettes smoked (P for trend = 0.003) and years of smoking (P for trend = 0.01). Other significant predictors of increased risk included low education and income and history of nonspecific genital infection. Unlike recent HPV DNA-based investigations, based on the use of HPV-seropositive controls in this study, oral contraceptive use was unrelated to the risk of cervical cancer and multiparity was only weakly related to risk. It is particularly worth considering further why studies of different designs are inconsistent regarding the effect of oral contraceptive use.
致癌性人乳头瘤病毒(HPV)感染是大多数宫颈癌的必要病因,这种感染很常见,通常在1至2年内自行清除。在HPV感染的女性中识别导致癌症的辅助因素主要依赖于通过DNA检测来定义HPV的病例对照研究。DNA检测仅评估当前感染情况;因此,对残留混杂因素的担忧依然存在。为了评估辅助因素,我们将对五种致癌性HPV类型的血清阳性作为过去接触的标志物,并将分析局限于与癌症病例相比的血清阳性对照。研究对象参与了20世纪80年代初在美国进行的一项多中心病例对照研究。针对235例鳞状细胞癌病例和486例对照的详细问卷及储存血清促使了此次重新分析。我们检测了针对HPV 16、18、31、45和52型的抗体。对照中血清阳性的独立显著预测因素包括性伴侣数量、黑人种族和口服避孕药的使用。使用避孕套具有保护作用。在HPV暴露的女性中,巴氏涂片筛查、黑人种族和酵母菌感染与降低癌症风险显著相关。当前吸烟与风险增加2倍相关;吸烟数量(趋势P值 = 0.003)和吸烟年限(趋势P值 = 0.01)存在独立且显著的风险增加趋势。其他风险增加的显著预测因素包括低教育程度、低收入以及非特异性生殖器感染史。与近期基于HPV DNA的调查不同,基于本研究中使用HPV血清阳性对照,口服避孕药的使用与宫颈癌风险无关,多胎妊娠与风险仅呈微弱相关。特别值得进一步思考为什么不同设计的研究在口服避孕药使用的影响方面存在不一致。